Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Allergan expands ophthalmic allergy product portfolio

Dec. 21, 1999

Swiss regulatory authorities grant Visudyne Therapy its first approval

Dec. 20, 1999

Pharmos seeks approval for Loterox in the U.K.

Dec. 20, 1999

New to the U.K. market: ophthalmic steroid from Alcon causes less IOP elevation

Dec. 16, 1999

AEterna presents promising phase I data for AE-941 in AMD

Dec. 13, 1999

Cambridge NeuroScience and Allergan extend ophthalmic research collaboration

Dec. 9, 1999

Projected enrollment exceeded in Miravant's phase III AMD trials

Dec. 8, 1999

Ciba Vision licenses Destiny's photodynamic therapy technology

Dec. 6, 1999

FDA advisory panel recommends approval of Visudyne therapy for wet AMD

Nov. 18, 1999

Ciba Vision introduces ocular formulation of lomefloxacin in U.K.

Nov. 15, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...